Nuo Therapeutics, Inc. (AURX) Operating margin 2017–2025
Nuo Therapeutics, Inc. (AURX) operating margin by fiscal year — reported operating income divided by reported revenue.
-76.0%FY2025 · since FY2017: -2154.4% → -76.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -76.0% | +104.1 pp |
| FY2024 | -180.0% | +340.6 pp |
| FY2023 | -520.6% | +2437.6 pp |
| FY2022 | -2958.2% | — |
| FY2019 | -663.0% | -553.2 pp |
| FY2018 | -109.8% | +2044.6 pp |
| FY2017 | -2154.4% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More AURX financial trends
AURX RevenueAURX Net incomeAURX Net marginAURX Gross profitAURX Gross marginAURX Operating incomeAURX Operating cash flowAURX Free cash flowAURX Capital expendituresAURX Return on equityAURX Stock buybacksAURX Dividends paidAURX Total assetsAURX Total liabilitiesAURX Shareholders’ equityAURX overview →